# US 2010/0168239 A1 · Use of Rasagiline for the Treatment of Multiple System Atrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168239 A1
- Document ID: US20100168239A1
- Status: Published application
- Kind: A1
- Application number: 12/223,794
- Filed: 2007-02-21
- Published: 2010-07-01
- Earliest claimed: 2006-02-21
- Assignees: Teva Pharmaceutical Industries Ltd.
- Inventors: Werner Poewe
- Web page: https://patentgrep.com/patent/US20100168239A1

## CPC

- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 31/195: having an amino group
- A61K 31/277: having a ring, e.g. verapamil
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/10: for impotence
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a method for the treatment of Multiple System Atrophy comprising administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating a subject suffering from Multiple System Atrophy, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to treat the subject.

### Claim 2

A method of alleviating a symptom of Multiple System Atrophy in a subject afflicted with Multiple System Atrophy, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to alleviate the symptom of Multiple System Atrophy in the subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein the symptoms of Multiple System Atrophy is tremor, muscular rigidity, hypokinesia, impaired balance, impaired speech, impaired swallowing, ataxia, orthostatic hypotension, impotence, urinary incontinence or urinary retention.

### Claim 4 (depends on 1)

The method of claim 1, wherein the form of multiple system atrophy is a striatonigral degeneration form, a Shy-Drager syndrome form, or a sporadic olivopontocerebellar atrophy form.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amount of R(+)-N-propargyl-1-aminoindan or of the pharmaceutically acceptable salt thereof is from 0.01 mg to 20 mg per day.

### Claim 6 (depends on 5)

The method of claim 5, wherein the amount of R(+)-N-propargyl-1-aminoindan or of the pharmaceutically acceptable salt thereof is from 0.5 mg to 5 mg per day.

### Claim 7 (depends on 5)

The method of claim 5, wherein the amount of R(+)-N-propargyl-1-aminoindan or of the pharmaceutically acceptable salt thereof is 2 mg per day.

### Claim 8 (depends on 5)

The method of claim 5, wherein the amount of R(+)-N-propargyl-1-aminoindan or of the pharmaceutically acceptable salt thereof is 1 mg per day.

### Claim 9 (depends on 1)

The method of claim 1, wherein the administration is of the pharmaceutically acceptable salt of R{+)-N-propargyl-1-aminoindan.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pharmaceutically acceptable salt is esylate, mesylate, sulfate or tartrate.

### Claim 11 (depends on 10)

The method of claim 10, wherein the pharmaceutically acceptable salt is mesylate.

### Claim 12 (depends on 11)

The method of claim 11, wherein the amount of R(+)-N-propargyl-1-aminoindan mesylate is 1.56 mg per day.

### Claim 13 (depends on 1)

The method of claim 1, wherein the administration is oral, parenteral, rectal or transdermal administration.

### Claim 14 (depends on 1)

The method of claim 1, further comprising administration of adjunctive therapy including, but not limited to, levodopa, dopamine agonists, glutamine antagonists, orthostatic hypotension therapeutics, anticholinergics, or drugs to treat male impotence.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject at the time of first administration of R(+)-N-propargyl-1-aminoindan mesylate or a pharmaceutically acceptable salt thereof has been receiving an adjunctive therapy including, but not limited to, levodopa, dopamine agonists, glutamine antagonists, orthostatic hypotension therapeutics, anticholinergics, or drugs to treat male impotence for the alleviation of a symptom of Multiple System Atrophy.

### Claim 16 (depends on 1)

The method of claim 1, wherein the R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is in a pharmaceutical composition.

### Claim 17

A pharmaceutical composition comprising in unit dosage form R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and at least one of dopamine agonists, glutamine antagonists, orthostatic hypotension therapeutics, anticholinergics, or drugs to treat male impotence.

### Claim at position 18

18-22. (canceled)

### Claim 23 (depends on 2)

The method of claim 2, wherein the form of multiple system atrophy is a striatonigral degeneration form, a Shy-Drager syndrome form, or a sporadic olivopontocerebellar atrophy form.

### Claim 24 (depends on 2)

The method of claim 2, wherein the amount of R(+)-N-propargyl-1-aminoindan or of the pharmaceutically acceptable salt thereof is from 0.01 mg to 20 mg per day.

### Claim 25 (depends on 24)

The method of claim 24, wherein the amount of R(+)-N-propargyl-1-aminoindan or of the pharmaceutically acceptable salt thereof is from 0.5 mg to 5 mg per day.